New article accepted: Micheels & Poiraud, 2023

Congratulations to Dr. Micheels and Dr. Poiraud for the publication of their article in the Journal of Clinical and Cosmetic Dermatology on the safety and efficacy of a new hyaluronic acid product, MaiLi. We are proud to have participated in the success of this article.

The use of injectable products to fill wrinkles dates back to the 1980s and the use of hyaluronic acid (HA) gels to the late 1990s. A large number of products have been developed since then, including the MaiLi formulation, developed with OxyFreeTM technology by Sinclair Pharma. This new product is based on the cross-linking of HA in an inert atmosphere and the extraction of reactive oxygen during the manufacturing process.

A total of 45 patients were injected with the MaiLi product. Most patients were very satisfied or satisfied with the post-injection results, even after 1 year, except for one patient. No serious adverse events were observed. Treatment-related adverse events of very low intensity and transient nature were reported in less than 5% of cases.

MaiLi HA gels, based on OxyFreeTM technology, are therefore well tolerated and safe, with long-term persistence of effects. No product-related adverse effects have been observed. The article is already available on the journal's website!